搜索

Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS
Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS
Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS

Why Choose Us?

Let China use globally innovative vaccines, and let the world use high-quality vaccines from China!

quanfu quanfu

Strong Corporate Strength

Ab&B Bio-Tech CO.,LTD.JS has a registered capital of 360 million yuan, a total area of 173 acres, and a total construction area of 228000 square meters. The No.1 production park covers an area of 69 acres, with a building area of 80000 square meters and a project investment of 1 billion yuan; The second production park covers an area of 72 acres, with a building area of 120000 square meters and a project investment of 2 billion yuan; The No. 3 Production Park covers an area of 32 acres, with a building area of 28000 square meters and a project investment of 600 million yuan

quanfu quanfu

Products & Services

Committed to the research and development, registration and application, industrial production and sales of innovative vaccines for human use, targeting international standards, and conducting independent innovative research and development.

quanfu quanfu

Scientific Research Capability

Shanghai/Taizhou R&D Center and pilot platform are promoting multiple viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccine pipelines simultaneously.

Product Pipelines

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Quadrivalent Subunit Influenza Vaccine（0.5ml）

Quadrivalent Subunit Influenza Vaccine（0.5ml）

This strain is made by inoculating chicken embryos with type A and type B influenza virus strains recommended by the World Health Organization (WHO), after cultivation, harvesting virus liquid, ultrafiltration concentration, virus splitting centrifugation, purification, virus inactivation, and then purifying and harvesting haemagglutinin and neuraminidase.

More Product Series

News Center

Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants
2024-08-26

On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
→

Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou
2024-08-14

Recently, the Science and Technology Bureau of Taizhou City announced the first batch of offshore innovation centers for enterprises, and Ab&B Bio Tech Co., Ltd (hereafter referred to as "Zhonghui Bio") wholly-owned subsidiary Yither Biotech (Shanghai) Co., Ltd (Yither Bio) Successfully obtained recognition.
→

Recombinant herpes zoster vaccine (CHO cells) IND application approved
2024-08-13

On August 12, 2024, Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (Zhonghui Biotechnology) and its subsidiary Yihui Biotechnology (Shanghai) Co., Ltd. (Yihui Biotechnology) jointly applied for an IND application for a Class I new drug, "Recombinant Herpes zoster Vaccine (CHO Cells)", which was approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration.
→

Have a project？Get a touch!

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Contact

E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Quick view

Follow us

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Verification 苏ICP备16005775号-1
Search